Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34
datasets available to search
ShareScore release 0.9.0
Dataset results
34 results for “Neuropsychiatric symptoms”
Supplemental Materials Eikelboom et al. Neuropsychiatric and cognitive symptoms across the Alzheimer's disease clinical spectrum
<p>The objective of this study was to investigate the prevalence and trajectories of neuropsychiatric symptoms (NPS) in relation to cognitive functioning in a cohort of amyloid-<em>β</em> positive individuals across the Alzheimer's disease (AD) clinical spectrum. In this single-center observational study, we included all individuals who visited the Alzheimer Center Amsterdam and had 1) a clinical diagnosis of subjective cognitive decline (SCD), mild cognitive impairment (MCI), or probable AD dementia, and 2) were amyloid-<em>β</em> positive (A+). We measured NPS with the Neuropsychiatric Inventory (NPI), examining total scores and the presence of specific NPI domains. Cognition was assessed across five cognitive domains and with the MMSE. We examined trajectories including model based trends for NPS and cognitive functioning over time. We used linear mixed models to relate baseline NPI scores to cognitive functioning at baseline (whole-sample) and longitudinal time-points (subsample n=520, Mean=1.8 [SD=0.7] years follow-up). We included 1,524 amyloid-β positive individuals from the Amsterdam Dementia Cohort with A+ SCD (n=113), A+ MCI (n=321), or A+ AD dementia (n=1,090). NPS were prevalent across all clinical AD stages (≥1 NPS 81.4% in SCD, 81.2% in MCI, 88.7% in dementia; ≥1 clinically relevant NPS 54.0% in SCD, 50.5% in MCI, 66.0% in dementia). Cognitive functioning showed an uniform gradual decline; while in contrast, large intra-individual heterogeneity of NPS was observed over time across all AD groups. At baseline, we found associations between NPS and cognition in dementia that were most pronounced for NPI total scores and MMSE (range <em>β</em>=0.18 to 0.11, FDR-adjusted <em>p</em><0.05), while there were no cross-sectional relationships in SCD and MCI (range <em>β</em>=-0.32 to 0.36, all FDR-adjusted <em>p</em>>0.05). There were no associations between baseline NPS and cognitive functioning over time in any clinical stage (range <em>β</em>=-0.13 to 0.44, all FDR-adjusted <em>p</em>>0.05). NPS and cognitive symptoms are both prevalent across the AD continuum, but show a different evolution during the course of the disease.</p>
Improving neuropsychiatric symptoms following stroke using virtual reality: A case report
<p>Post-stroke cognitive impairment occurs frequently in patients with stroke, with a 20% to 80% prevalence. Anxiety is common after stroke, and is associated with a poorer quality of life. The use of standard relaxation techniques in treating anxiety in patients undergoing post-stroke rehabilitation have shown some positive effects, whereas virtual reality seems to have a role in the treatment of anxiety disorders, especially when associated to neurological damage. A 50-year-old woman, smokers, affected by hypertension and right ischemic stroke in the chronic phase (i.e., after 12 months by cerebrovascular event), came to our observation for a severe anxiety state and a mild cognitive deficit, mainly involving attention and visuo-executive processes, besides a mild left hemiparesis. Anxiety in a patient with ischemic stroke. Standard relaxation techniques alone in a common clinical setting or the same psychological approach in an immersive virtual environment (i.e., Computer Assisted Rehabilitation Environment – CAREN). The patient's cognitive and psychological profile, with regard to attention processes, mood, anxiety, and coping strategies, were evaluated before and after the 2 different trainings. A significant improvement in the functional and behavioral outcomes were observed only at the end of the combined approach.The immersive virtual reality environment CAREN might be useful to improve cognitive and psychological status, with regard to anxiety symptoms, in post-stroke individuals.</p>
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
ClinicalTrials.gov study NCT01114737. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
ClinicalTrials.gov study NCT00749944. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
ClinicalTrials.gov study NCT03575052. IPD Sharing: NO. Countries: 12. Publications: 1.
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
ClinicalTrials.gov study NCT01712074. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Supplemental Materials Eikelboom et al. Neuropsychiatric and cognitive symptoms across the Alzheimer's disease clinical spectrum
Open the record for dataset details and reuse information.
Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms
ClinicalTrials.gov study NCT06633666. IPD Sharing: Not stated. Countries: 1. Publications: 15.
EEG-characteristics of Neuropsychiatric Symptoms in Chronic Pain
ClinicalTrials.gov study NCT05261243. IPD Sharing: YES. Countries: 1. Publications: 3.
Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia
ClinicalTrials.gov study NCT03672201. IPD Sharing: NO. Countries: 1. Publications: 3.
Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms
ClinicalTrials.gov study NCT02472015. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
ClinicalTrials.gov study NCT00769353. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.
ClinicalTrials.gov study NCT07287410. IPD Sharing: NO. Countries: 1. Publications: 0.
Electro-acupuncture for Long Covid Neuropsychiatric Symptoms
ClinicalTrials.gov study NCT05890508. IPD Sharing: UNDECIDED. Countries: 1. Publications: 26.
Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)
ClinicalTrials.gov study NCT04004702. IPD Sharing: NO. Countries: 1. Publications: 45.
An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia
ClinicalTrials.gov study NCT01102582. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
ClinicalTrials.gov study NCT05497089. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease
ClinicalTrials.gov study NCT06835283. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
ClinicalTrials.gov study NCT04164758. IPD Sharing: NO. Countries: 1. Publications: 0.
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)
ClinicalTrials.gov study NCT02367521. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.